Literature DB >> 17703252

Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.

Denny Demeria1, Iain Birchall, Vincent G Bain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17703252      PMCID： PMC2657977          DOI： 10.1155/2007/128792

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  7 in total

1.  Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.

Authors:  Yehuda Z Patt; Manal M Hassan; Richard D Lozano; Ajay K Nooka; Isaac I Schnirer; Jerome B Zeldis; James L Abbruzzese; Thomas D Brown
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

2.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.

Authors:  K S Bauer; S C Dixon; W D Figg
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858

3.  Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Authors:  Chiun Hsu; Chiung-Nien Chen; Li-Tzong Chen; Chen-Yao Wu; Pei-Ming Yang; Ming-Yang Lai; Po-Huang Lee; Ann-Lii Cheng
Journal:  Oncology       Date:  2003       Impact factor: 2.935

Review 4.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

5.  Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.

Authors:  Her-Shyong Shiah; Yee Chao; Li-Tzong Chen; Tzy-Jyun Yao; Jin-Ding Huang; Jang-Yang Chang; Pei-Jer Chen; Tsai-Rong Chuang; Yung-Hsin Chin; Jacqueline Whang-Peng; Tsang-Wu Liu
Journal:  Cancer Chemother Pharmacol       Date:  2006-03-07       Impact factor: 3.333

6.  A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

Authors:  Man-Fung Yuen; Ronnie Tung-Ping Poon; Ching-Lung Lai; Sheung-Tat Fan; Chung-Mau Lo; Ka-Wah Wong; Wai Man Wong; Benjamin Chun-Yu Wong
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

Review 7.  Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma.

Authors:  Jonathan D Schwartz; Andreas S Beutler
Journal:  Anticancer Drugs       Date:  2004-06       Impact factor: 2.248
  7 in total
  1 in total

Review 1.  Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  De-Dong Cao; Hui-Lin Xu; Liang Liu; Yong-Fa Zheng; Si-Fa Gao; Xi-Ming Xu; Wei Ge
Journal:  Oncotarget       Date:  2017-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.